company background image
CYTR

CytRx OTCPK:CYTR Stock Report

Last Price

US$0.13

Market Cap

US$5.5m

7D

18.1%

1Y

-90.3%

Updated

18 May, 2022

Data

Company Financials
CYTR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

CYTR Stock Overview

CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases.

CytRx Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for CytRx
Historical stock prices
Current Share PriceUS$0.13
52 Week HighUS$4.70
52 Week LowUS$0.094
Beta2.17
1 Month Change1.56%
3 Month Change-71.89%
1 Year Change-90.30%
3 Year Change-76.99%
5 Year Change-95.70%
Change since IPO-99.98%

Recent News & Updates

Shareholder Returns

CYTRUS BiotechsUS Market
7D18.1%5.7%0.5%
1Y-90.3%-21.4%-11.5%

Return vs Industry: CYTR underperformed the US Biotechs industry which returned -19.5% over the past year.

Return vs Market: CYTR underperformed the US Market which returned -8.1% over the past year.

Price Volatility

Is CYTR's price volatile compared to industry and market?
CYTR volatility
CYTR Average Weekly Movement19.2%
Biotechs Industry Average Movement12.4%
Market Average Movement7.9%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.0%

Stable Share Price: CYTR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.

Volatility Over Time: CYTR's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
19853Stephen Snowdyhttps://www.cytrx.com

CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company’s lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed cytotoxin agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor.

CytRx Fundamentals Summary

How do CytRx's earnings and revenue compare to its market cap?
CYTR fundamental statistics
Market CapUS$5.47m
Earnings (TTM)-US$13.57m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CYTR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$13.57m
Earnings-US$13.57m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.31
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did CYTR perform over the long term?

See historical performance and comparison

Valuation

Is CytRx undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


4.46x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CYTR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CYTR's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: CYTR is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CYTR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CYTR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CYTR is overvalued based on its PB Ratio (4.5x) compared to the US Biotechs industry average (1.5x).


Future Growth

How is CytRx forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


11.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CytRx has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has CytRx performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


41.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CYTR is currently unprofitable.

Growing Profit Margin: CYTR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CYTR is unprofitable, but has reduced losses over the past 5 years at a rate of 41.1% per year.

Accelerating Growth: Unable to compare CYTR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYTR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: CYTR has a negative Return on Equity (-402.5%), as it is currently unprofitable.


Financial Health

How is CytRx's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CYTR's short term assets ($6.2M) exceed its short term liabilities ($3.1M).

Long Term Liabilities: CYTR's short term assets ($6.2M) exceed its long term liabilities ($186.1K).


Debt to Equity History and Analysis

Debt Level: CYTR is debt free.

Reducing Debt: CYTR has no debt compared to 5 years ago when its debt to equity ratio was 163.5%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CYTR has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CYTR has less than a year of cash runway if free cash flow continues to grow at historical rates of 40.5% each year.


Dividend

What is CytRx current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CYTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CYTR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CYTR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CYTR's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CYTR has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Stephen Snowdy (51 yo)

0.33

Tenure

Dr. Stephen Snowdy, Ph D., serves as Chief Executive Officer at CytRx Corporation since January 10, 2022. He served as Chief Executive Officer of Visioneering Technologies, Inc. since June 2013 until Janua...


Leadership Team

Experienced Management: CYTR's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

Experienced Board: CYTR's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.2%.


Top Shareholders

Company Information

CytRx Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: CytRx Corporation
  • Ticker: CYTR
  • Exchange: OTCPK
  • Founded: 1985
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$5.475m
  • Shares outstanding: 43.48m
  • Website: https://www.cytrx.com

Number of Employees


Location

  • CytRx Corporation
  • 11726 San Vicente Boulevard
  • Suite 650
  • Los Angeles
  • California
  • 90049
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/18 00:00
End of Day Share Price2022/05/18 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.